Higgins JE - Search Results

1

Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora) versus placebo in postmenopausal women experiencing menopausal symptoms. Alora Study Group.

Good WR, John VA, Ramirez M, Higgins JE. Good WR, et al. Among authors: higgins je. Clin Ther. 1996 Nov-Dec;18(6):1093-105. doi: 10.1016/s0149-2918(96)80064-6. Clin Ther. 1996. PMID: 9001826 Clinical Trial.

2

Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.

Good WR, John VA, Ramirez M, Higgins JE. Good WR, et al. Among authors: higgins je. Climacteric. 1999 Mar;2(1):29-36. doi: 10.3109/13697139909025560. Climacteric. 1999. PMID: 11915854 Clinical Trial.

3

Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.

Bradford RH, Shear CL, Chremos AN, Dujovne C, Franklin FA, Hesney M, Higgins J, Langendörfer A, Pool JL, Schnaper H, et al. Bradford RH, et al. Am J Cardiol. 1990 Sep 18;66(8):44B-55B. doi: 10.1016/0002-9149(90)90440-c. Am J Cardiol. 1990. PMID: 2206036 Clinical Trial.

4

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.

Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, Higgins J, Langendorfer A, Nash DT, Pool JL, et al. Bradford RH, et al. Am J Cardiol. 1994 Oct 1;74(7):667-73. doi: 10.1016/0002-9149(94)90307-7. Am J Cardiol. 1994. PMID: 7942524 Clinical Trial.

5

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.

Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, et al. Bradford RH, et al. Arch Intern Med. 1991 Jan;151(1):43-9. doi: 10.1001/archinte.151.1.43. Arch Intern Med. 1991. PMID: 1985608 Clinical Trial.

6

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.

Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, Higgins J, Downton M, Franklin FA, Nash DT, et al. Dujovne CA, et al. Am J Med. 1991 Jul 31;91(1B):25S-30S. doi: 10.1016/0002-9343(91)90053-z. Am J Med. 1991. PMID: 1831006 Clinical Trial.

7

Adopting duplex sequencing technology for genetic toxicity testing: A proof-of-concept mutagenesis experiment with N-ethyl-N-nitrosourea (ENU)-exposed rats.

Smith-Roe SL, Hobbs CA, Hull V, Todd Auman J, Recio L, Streicker MA, Rivas MV, Pratt GA, Lo FY, Higgins JE, Schmidt EK, Williams LN, Nachmanson D, Valentine Iii CC, Salk JJ, Witt KL. Smith-Roe SL, et al. Among authors: higgins je. Mutat Res Genet Toxicol Environ Mutagen. 2023 Oct;891:503669. doi: 10.1016/j.mrgentox.2023.503669. Epub 2023 Aug 3. Mutat Res Genet Toxicol Environ Mutagen. 2023. PMID: 37770135 Free PMC article.

8

Adopting Duplex Sequencing™ Technology for Genetic Toxicity Testing: A Proof-of-Concept Mutagenesis Experiment with N-Ethyl-N-Nitrosourea (ENU)-Exposed Rats.

Smith-Roe SL, Hobbs CA, Hull V, Auman JT, Recio L, Streicker MA, Rivas MV, Pratt GA, Lo FY, Higgins JE, Schmidt EK, Williams LN, Nachmanson D, Valentine CC 3rd, Salk JJ, Witt KL. Smith-Roe SL, et al. Among authors: higgins je. bioRxiv [Preprint]. 2023 May 9:2023.05.08.539833. doi: 10.1101/2023.05.08.539833. bioRxiv. 2023. Update in: Mutat Res Genet Toxicol Environ Mutagen. 2023 Oct;891:503669. doi: 10.1016/j.mrgentox.2023.503669. PMID: 37214853 Free PMC article. Updated. Preprint.

9

Early Results of Our International, Multicenter, Multisurgeon, Double-Blinded, Prospective, Randomized, Controlled Trial Comparing Metal-on-Metal With Ceramic-on-Metal in Total Hip Arthroplasty.

Higgins JE, Conn KS, Britton JM, Pesola M, Manninen M, Stranks GJ. Higgins JE, et al. J Arthroplasty. 2020 Jan;35(1):193-197.e2. doi: 10.1016/j.arth.2019.08.002. Epub 2019 Aug 22. J Arthroplasty. 2020. PMID: 31540737 Clinical Trial.

10

Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan.

Salk JJ, Loubet-Senear K, Maritschnegg E, Valentine CC, Williams LN, Higgins JE, Horvat R, Vanderstichele A, Nachmanson D, Baker KT, Emond MJ, Loter E, Tretiakova M, Soussi T, Loeb LA, Zeillinger R, Speiser P, Risques RA. Salk JJ, et al. Among authors: higgins je. Cell Rep. 2019 Jul 2;28(1):132-144.e3. doi: 10.1016/j.celrep.2019.05.109. Cell Rep. 2019. PMID: 31269435 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters